Long-term outcome of transcatheter embolization of renal angiomyolipomas due to tuberous sclerosis complex

David H. Ewalt, Norman Diamond, Chet Rees, Steven P. Sparagana, Mauricio Delgado, Lori Batchelor, E. Steve Roach

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Purpose: Complications from renal angiomyolipomas (AMLs) are common in patients with tuberous sclerosis complex (TSC) and tumors greater than 4 cm are more likely to cause symptoms. AMLs are the most common cause of death in adults with TSC. We present our long-term experience with transcatheter tumor embolization as a definitive treatment for AMLs due to TSC. Materials and Methods: A total of 16 patients with TSC between 7.5 and 47.2 years old with symptomatic or large (4 to 21 cm) AMLs underwent embolization. Followup consisted of periodic physician visits or telephone contacts and renal imaging. Results: The 16 patients underwent 18 treatment sessions to embolize 27 tumors. There were no intraoperative complications. The post-embolization syndrome occurred in 11 individuals but all responded to medical management. Two individuals had an arterial aneurysm within a tumor. The AML size decreased in the 13 patients who were imaged 3 months after treatment, and the 7 patients who were imaged 3 to 9 years after treatment have shown no tumor regrowth. No renal failure or hemorrhage has developed in patients following embolization. Conclusions: Transcatheter embolization of symptomatic or large AMLs due to TSC prevents hemorrhage and renal loss. The treatment is minimally invasive, preserves renal function, and can be performed multiple times. All of the patients who underwent followup renal imaging after embolization showed decreased AML size, and none of the 16 patients has developed renal loss or renal insufficiency in these individuals. Embolization should be considered the initial treatment of choice for large or symptomatic AMLs.

Original languageEnglish (US)
Pages (from-to)1764-1766
Number of pages3
JournalJournal of Urology
Volume174
Issue number5
DOIs
StatePublished - Nov 2005

Fingerprint

Angiomyolipoma
Tuberous Sclerosis
Kidney
Neoplasms
Renal Insufficiency
Therapeutics
Hemorrhage
Intraoperative Complications
Telephone
Aneurysm
Cause of Death
Physicians

Keywords

  • Embolization, therapeutic
  • Neoplasms
  • Tuberous sclerosis, angiomyolipoma

ASJC Scopus subject areas

  • Urology

Cite this

Long-term outcome of transcatheter embolization of renal angiomyolipomas due to tuberous sclerosis complex. / Ewalt, David H.; Diamond, Norman; Rees, Chet; Sparagana, Steven P.; Delgado, Mauricio; Batchelor, Lori; Roach, E. Steve.

In: Journal of Urology, Vol. 174, No. 5, 11.2005, p. 1764-1766.

Research output: Contribution to journalArticle

Ewalt, David H. ; Diamond, Norman ; Rees, Chet ; Sparagana, Steven P. ; Delgado, Mauricio ; Batchelor, Lori ; Roach, E. Steve. / Long-term outcome of transcatheter embolization of renal angiomyolipomas due to tuberous sclerosis complex. In: Journal of Urology. 2005 ; Vol. 174, No. 5. pp. 1764-1766.
@article{7ba141fa12ab4cda95eab39045217a95,
title = "Long-term outcome of transcatheter embolization of renal angiomyolipomas due to tuberous sclerosis complex",
abstract = "Purpose: Complications from renal angiomyolipomas (AMLs) are common in patients with tuberous sclerosis complex (TSC) and tumors greater than 4 cm are more likely to cause symptoms. AMLs are the most common cause of death in adults with TSC. We present our long-term experience with transcatheter tumor embolization as a definitive treatment for AMLs due to TSC. Materials and Methods: A total of 16 patients with TSC between 7.5 and 47.2 years old with symptomatic or large (4 to 21 cm) AMLs underwent embolization. Followup consisted of periodic physician visits or telephone contacts and renal imaging. Results: The 16 patients underwent 18 treatment sessions to embolize 27 tumors. There were no intraoperative complications. The post-embolization syndrome occurred in 11 individuals but all responded to medical management. Two individuals had an arterial aneurysm within a tumor. The AML size decreased in the 13 patients who were imaged 3 months after treatment, and the 7 patients who were imaged 3 to 9 years after treatment have shown no tumor regrowth. No renal failure or hemorrhage has developed in patients following embolization. Conclusions: Transcatheter embolization of symptomatic or large AMLs due to TSC prevents hemorrhage and renal loss. The treatment is minimally invasive, preserves renal function, and can be performed multiple times. All of the patients who underwent followup renal imaging after embolization showed decreased AML size, and none of the 16 patients has developed renal loss or renal insufficiency in these individuals. Embolization should be considered the initial treatment of choice for large or symptomatic AMLs.",
keywords = "Embolization, therapeutic, Neoplasms, Tuberous sclerosis, angiomyolipoma",
author = "Ewalt, {David H.} and Norman Diamond and Chet Rees and Sparagana, {Steven P.} and Mauricio Delgado and Lori Batchelor and Roach, {E. Steve}",
year = "2005",
month = "11",
doi = "10.1097/01.ju.0000177497.31986.64",
language = "English (US)",
volume = "174",
pages = "1764--1766",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Long-term outcome of transcatheter embolization of renal angiomyolipomas due to tuberous sclerosis complex

AU - Ewalt, David H.

AU - Diamond, Norman

AU - Rees, Chet

AU - Sparagana, Steven P.

AU - Delgado, Mauricio

AU - Batchelor, Lori

AU - Roach, E. Steve

PY - 2005/11

Y1 - 2005/11

N2 - Purpose: Complications from renal angiomyolipomas (AMLs) are common in patients with tuberous sclerosis complex (TSC) and tumors greater than 4 cm are more likely to cause symptoms. AMLs are the most common cause of death in adults with TSC. We present our long-term experience with transcatheter tumor embolization as a definitive treatment for AMLs due to TSC. Materials and Methods: A total of 16 patients with TSC between 7.5 and 47.2 years old with symptomatic or large (4 to 21 cm) AMLs underwent embolization. Followup consisted of periodic physician visits or telephone contacts and renal imaging. Results: The 16 patients underwent 18 treatment sessions to embolize 27 tumors. There were no intraoperative complications. The post-embolization syndrome occurred in 11 individuals but all responded to medical management. Two individuals had an arterial aneurysm within a tumor. The AML size decreased in the 13 patients who were imaged 3 months after treatment, and the 7 patients who were imaged 3 to 9 years after treatment have shown no tumor regrowth. No renal failure or hemorrhage has developed in patients following embolization. Conclusions: Transcatheter embolization of symptomatic or large AMLs due to TSC prevents hemorrhage and renal loss. The treatment is minimally invasive, preserves renal function, and can be performed multiple times. All of the patients who underwent followup renal imaging after embolization showed decreased AML size, and none of the 16 patients has developed renal loss or renal insufficiency in these individuals. Embolization should be considered the initial treatment of choice for large or symptomatic AMLs.

AB - Purpose: Complications from renal angiomyolipomas (AMLs) are common in patients with tuberous sclerosis complex (TSC) and tumors greater than 4 cm are more likely to cause symptoms. AMLs are the most common cause of death in adults with TSC. We present our long-term experience with transcatheter tumor embolization as a definitive treatment for AMLs due to TSC. Materials and Methods: A total of 16 patients with TSC between 7.5 and 47.2 years old with symptomatic or large (4 to 21 cm) AMLs underwent embolization. Followup consisted of periodic physician visits or telephone contacts and renal imaging. Results: The 16 patients underwent 18 treatment sessions to embolize 27 tumors. There were no intraoperative complications. The post-embolization syndrome occurred in 11 individuals but all responded to medical management. Two individuals had an arterial aneurysm within a tumor. The AML size decreased in the 13 patients who were imaged 3 months after treatment, and the 7 patients who were imaged 3 to 9 years after treatment have shown no tumor regrowth. No renal failure or hemorrhage has developed in patients following embolization. Conclusions: Transcatheter embolization of symptomatic or large AMLs due to TSC prevents hemorrhage and renal loss. The treatment is minimally invasive, preserves renal function, and can be performed multiple times. All of the patients who underwent followup renal imaging after embolization showed decreased AML size, and none of the 16 patients has developed renal loss or renal insufficiency in these individuals. Embolization should be considered the initial treatment of choice for large or symptomatic AMLs.

KW - Embolization, therapeutic

KW - Neoplasms

KW - Tuberous sclerosis, angiomyolipoma

UR - http://www.scopus.com/inward/record.url?scp=27544493736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27544493736&partnerID=8YFLogxK

U2 - 10.1097/01.ju.0000177497.31986.64

DO - 10.1097/01.ju.0000177497.31986.64

M3 - Article

C2 - 16217279

AN - SCOPUS:27544493736

VL - 174

SP - 1764

EP - 1766

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -